G. Kuesters

Publications16
h-index6
Citations148
Highly Influential Citations3
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • T. Plavina
  • 58 Publications, 2,422 Citations
  • M. Subramanyam
  • 54 Publications, 2,868 Citations
  • G. MacBeath
  • 108 Publications, 7,560 Citations
  • D. Kirpotin
  • 116 Publications, 8,750 Citations
  • Publications
  • Influence
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
Objective: To characterize the reversibility of natalizumab-mediated changes in pharmacokinetics/pharmacodynamics in patients with multiple sclerosis (MS) following therapy interruption. Methods:… Expand
  • 28
  • 1
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models
Antibody-mediated tumour targeting and nanoparticle-mediated encapsulation can reduce the toxicity of antitumour drugs and improve their efficacy. Here, we describe the performance of a… Expand
  • 13
  • 1
Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis
Natalizumab (humanized immunoglobulin G4 antibody targeting alpha‐4 integrins) is a highly efficacious treatment for relapsing‐remitting multiple sclerosis (RRMS) that has been in clinical use since… Expand
  • 19
  • 1
Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg/mL levels of cytokines in human serum.
A comprehensive cross-platform and cross-assay evaluation using nine technology platforms and four cytokine immunoassays (IL-6, TNFα, IL-17a, IL-2) was performed by comparing assay precision,… Expand
  • 34
Anti-JC Virus (JCV) Antibody Index Differentiates Risk of Progressive Multifocal Leukoencephalopathy (PML) in Natalizumab-Treated Multiple Sclerosis (MS) Patients with No Prior Immunosuppressant (IS)…
OBJECTIVE: To evaluate associations of anti-JCV antibody index with PML risk in natalizumab-treated MS patients without prior IS use (no-IS patients), using a recent data set. BACKGROUND: PML risk… Expand
  • 12
IV immunoglobulin confounds JC virus antibody serostatus determination
Objective: To determine the impact of therapeutic infusion of IV immunoglobulin (IVIg) on John Cunningham virus antibody (JCV Ab) serostatus and level in serum. Methods: We carried out a… Expand
  • 12
Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration
BackgroundMany studies have focused on the challenges of small molecule uptake across the blood–brain barrier, whereas few in-depth studies have assessed the challenges with the uptake of antibodies… Expand
  • 16
Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy
Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML) comprises the anti-JC virus (JCV) antibody index (AI). The anti-JCV AI was longitudinally determined in… Expand
  • 5
  • PDF
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
BACKGROUND Seribantumab (MM-121) is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3/ErbB3) to block heregulin (HRG/NRG)-mediated ErbB3 signaling… Expand
  • 5
SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).
9036Background: Seribantumab (MM-121) is a human monoclonal IgG2 antibody that blocks the HRG domain of HER3. Preclinical data suggest that seribantumab reverses HRG mediated drug resistance across...
  • 1